News

Absolute Risk of Atypical Fractures is Low in Bisphosphonate Users

Publish date: March 8, 2011

 

FROM JAMA

One of the coauthors – Muhammad M. Mamdani, Pharm.D., – reported financial relationships with Boehringer Ingelheim, Janssen-Ortho, Novartis, and Pfizer. The study was funded by the Ontario Ministry of Health and Long-Term Care.

Pages

Recommended Reading

Lower BMI, More Exercise May Mitigate Risk of Triple-Negative Breast Cancers
MDedge Family Medicine
Women Remain Underrepresented in Heart Device Studies
MDedge Family Medicine
Topical Steroids Found to Double Fetal Growth-Retardation Risk
MDedge Family Medicine
Eribulin Extends Survival of Women With Heavily Pretreated Breast Cancer
MDedge Family Medicine
Plastic Surgery Groups Remove Cancer-Implant Webinar After Complaints
MDedge Family Medicine
Data Link High Oral Cleft Risk to Topiramate
MDedge Family Medicine
Single Embryo Transfers Increase in 2009
MDedge Family Medicine
Tailor Antibiotic Dose to Weight Before Cesarean
MDedge Family Medicine
Optimal Therapy Elusive for Many Ovarian Cancer Patients With Medicare
MDedge Family Medicine
Zoledronic Acid Cuts Fractures in Osteoporotic Women at All Fracture-Risk Levels
MDedge Family Medicine